Evidence map›Paper›PMID 38274098›Full record

ArticleFrontiers in molecular biosciences2023

Classification of clinically actionable genetic mutations in cancer patients.

Muhammad Shahzad, Muhammad Rafi, Wadee Alhalabi, Naz Minaz Ali, Muhammad Shahid Anwar, Sara Jamal, Muskan Barket Ali, Fahad Abdullah Alqurashi

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Muhammad ShahzadNational University of Computer and Emerging Sciences, Karachi, Pakistan.
Muhammad RafiNational University of Computer and Emerging Sciences, Karachi, Pakistan.
Wadee AlhalabiDepartment of Computer Science, Immersive Virtual Reality Research Group, King Abdulaziz University, Jeddah, Saudi Arabia.
Naz Minaz AliNational University of Computer and Emerging Sciences, Karachi, Pakistan.
Muhammad Shahid AnwarDepartment of AI and Software, Gachon University, Seongnam-si, Republic of Korea.
Sara JamalNational University of Computer and Emerging Sciences, Karachi, Pakistan.
Muskan Barket AliNational University of Computer and Emerging Sciences, Karachi, Pakistan.
Fahad Abdullah AlqurashiDepartment of Computer Science, Faculty of Computing and Information Technology, Jeddah, Saudi Arabia.
National University of Computer and Emerging Sciences · PKDar Al-Hekma University · SAGachon University · KRJeddah University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Personalized medicine in cancer treatment aims to treat each individual's cancer tumor uniquely based on the genetic sequence of the cancer patient and is a much more effective approach compared to traditional methods which involve treating each type of cancer in the same, generic manner. However, personalized treatment requires the classification of cancer-related genes once profiled, which is a highly labor-intensive and time-consuming task for pathologists making the adoption of personalized medicine a slow progress worldwide. In this paper, we propose an intelligent multi-class classifier system that uses a combination of Natural Language Processing (NLP) techniques and Machine Learning algorithms to automatically classify clinically actionable genetic mutations using evidence from text-based medical literature. The training data set for the classifier was obtained from the Memorial Sloan Kettering Cancer Center and the Random Forest algorithm was applied with TF-IDF for feature extraction and truncated SVD for dimensionality reduction. The results show that the proposed model outperforms the previous research in terms of accuracy and precision scores, giving an accuracy score of approximately 82%. The system has the potential to revolutionize cancer treatment and lead to significant improvements in cancer therapy.

Indexed as

genetic mutationsmachine learningnatural language processingpersonalized medicineprecision medicine

Identifiers

PMID38274098
PMCPMC10808303
OpenAlexW4390742979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.